Preclinical studies have demonstrated that vebrertinib is effective in various tumor types with MET driver alterations and in overcoming MET amplification-dependent resistance to EGFR therapy in EGFR-positive non-small cell lung cancer.
FOSTER CITY, Calif., April 10, 2024 (Globe Newswire) — Apollomics Inc. (“Apollomics” or the “Company”) is a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers. ) presented two posters. Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10, 2024, San Diego, California. A copy of the poster is available on the Apollomics website at ir.apollomicsinc.com/news-events/presentations.
“The selectivity and high in vivo “Efficacy against multiple tumor types in different patient-derived tumor models demonstrates the potential for single agents or combinations to treat a variety of MET-altered tumors,” said Dr. Guo-Liang Yu, Chairman and Chief Executive Officer. says. Apollomics. “Based on patient-established preclinical models, we believe that vebrertinib may provide meaningful clinical benefit toward overcoming or preventing MET amplification-dependent resistance in patients with EGFR-positive non-small cell lung cancer (NSCLC).” We are thinking.”
Presented under the title “Bebrertinib: a novel brain-penetrant MET kinase inhibitor demonstrates mechanism of action and pharmacological antitumor activity in diverse patient-derived MET-dysregulated tumor models at clinically relevant drug levels.” The first poster published showed that vebrertinib is effective in treating patient-derived tumors from diverse organ sites and genomic alterations such as MET exon 14 skipping, MET fusions, MET amplification, or overexpression of MET and hepatocyte growth factor in clinically relevant agents. A novel potent and selective MET kinase inhibitor showing promising preclinical activity against MET kinases provides proof of concept for continued clinical development.
The second poster presented was entitled “Dependence of EGFR-mutant NSCLC on MET demonstrated by vebrertinib, a novel and selective brain-penetrating MET kinase inhibitor,” which showed that adding vebrertinib to EGFR therapy Demonstrated overcoming MET amplification-dependent resistance with sustained or long-lasting effects. Prevents MET-dependent tolerance and maximizes therapeutic efficacy.
About vebrertinib (APL-101)
Bebrertinib is a potent, small molecule, orally bioavailable, brain penetrating, and highly selective c-MET inhibitor. It works by inhibiting aberrant activation of the HGF/MET axis, a key pathway involved in tumor growth, proliferation, and development of resistance to certain targeted therapies, such as osimertinib. By targeting MET dysregulation, vebrertinib has the potential to provide breakthroughs in many cancers caused by altered MET.
Bebrertinib has demonstrated potent tumor suppressive effects in various preclinical c-MET dysregulated human gastric, liver, pancreatic, and lung cancer xenograft animal models and patient-derived xenograft models (PDX). In a phase 1 clinical trial, vebrertinib (vozitinib or PLB1001) showed preliminary evidence of clinical activity in NSCLC patients with mutations leading to MET exon 14 skipping and in secondary glioblastoma multiforme (sGBM) patients with MET fusions. showed a generally well-tolerated safety profile. and/or exon 14 skipping with evidence of brain entry. In China, vebreltinib is called vozitinib, or PLB1001, and is being developed by Apollomics partner Aviston Biotechnology. The KUNPENG research results were presented at the 2023 European Society of Medical Oncology Congress on October 23, 2023. showed that a vebrertinib-treated patient with locally advanced or metastatic NSCLC harboring a c-MET exon 14 skipping mutation achieved an overall response rate (ORR) of 75%. Among other notable findings, ORR and DCR were 100% for patients with brain metastases (n=5) and 66.7% for patients with liver metastases (n=6).
More information about the Phase 1/2 SPARTA global clinical trial is available at clinicaltrials.gov: NCT03175224. In addition to developing vebreretinib as a single-agent cancer treatment, Apollomics is actively evaluating the potential of vebreretinib in combination with novel therapies in a variety of tumor types. Bebrertinib has received conditional approval from the National Medical Products Administration (NMPA) of China.
About Apollomics Co., Ltd.
Apollomics Inc. is an innovative company focused on discovering and developing oncology therapies that harness the immune system and have the potential to be combined with other therapies to inhibit cancer by targeting specific molecular pathways. A clinical-stage biopharmaceutical company. Apollomics currently has a pipeline of nine of his drug candidates across multiple programs, six of which are currently in clinical development. Apollomics' major programs include bebrertinib (APL-101), a potent selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and specific therapeutics. Contains Uproletheran (APL-106). E-selectin antagonists that may be used adjunct to standard chemotherapy to treat acute myeloid leukemia. For more information, please visit www.apollomicsinc.com.
Cautionary note regarding forward-looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Exchange Act. Masu. As amended in 1934 (“Exchange Law”). All statements other than statements of current or historical fact contained in this press release are forward-looking statements. As used in this press release, “may,” “could,” “should,” “would,” “might,” “believe,” “estimated” “,” “expected,” “anticipated,” “future,” the negative of such terms, and other similar expressions are intended to identify forward-looking statements, but all No such identifiers are included in forward-looking statements. Apollomics cautions you that its forward-looking statements involve unknown risks and uncertainties that could cause actual results to differ materially from those indicated in the company's forward-looking statements. Masu. (i) the impact of current or new government regulations in the United States and China affecting Apollomics' operations and the continued listing of Apollomics securities; (ii) failure to achieve favorable clinical results or to license third party intellectual property rights for future discovery and development of Apollomics' oncology projects; (iii) failure to commercialize product candidates and market acceptance of such product candidates; (iv) the inability to protect intellectual property and the risk of legal claims, proceedings, litigation or other types of disputes relating to Apollomics' business, licenses or intellectual property; (v) breach of data security; (vi) the risk that Apollomics may be unable to develop and maintain effective internal controls; (vii) adverse changes to the regulatory environment; and as discussed in Apollomics' Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (the “SEC”) on March 28, 2024. risks and uncertainties. “Risk Factors” and other documents we file or file with the SEC. Additional information regarding these and other factors that may affect us is contained in the reports that Apollomics has filed with the SEC from time to time. These SEC filings are available on the SEC's website at www.sec.gov. Forward-looking statements speak only as of the date they are made by us. Except to the extent required by applicable law, Apollomics does not disclose any information to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements. , undertakes no obligation to publicly update any forward-looking statements.
contact address
PR for investors
peter vozzo
ICR Westwick
Peter.Vozzo@westwicke.com
443-213-0505
Media contact point
Sean Reus
ICR Westwick
Sean.Leous@westwicke.com
646-866-4012